Korro’s lead program for alpha-1 antitrypsin deficiency (AATD) has underperformed in early testing, prompting the company to announce a significant restructuring that includes laying off a third of its workforce. This disappointing outcome highlights the challenges faced by biotech firms in the highly competitive RNA editing space, where expectations for efficacy are often set high. The decision to pivot comes as Korro reassesses its pipeline and strategic focus, indicating a potential shift towards more viable therapeutic avenues.
As the market for RNA-based therapies continues to evolve, Korro’s experience serves as a cautionary tale for other companies in the sector. The implications of these layoffs extend beyond immediate cost-cutting; they reflect a broader trend of recalibrating research priorities in response to clinical data. Industry stakeholders must now consider how such setbacks may influence investor confidence and the overall landscape for RNA therapeutics.
Start your 7-day trial and see what the database can do →
